RecallRadar

FDA Drug recall D-0092-2024

Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, P…

On 2023-11-15 the FDA classified a Class II recall of Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, P… by Glenmark Pharmaceuticals Usa, citing failed Dissolution Specifications: Out of specification for dissolution.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0092-2024
ClassificationClass II
Statusongoing
Initiated2023-10-23
Published2023-11-15
Last updated2026-09-13 11:52 UTC
CompanyGlenmark Pharmaceuticals Usa
DistributionUS

Product

Ranolazine Extended-Release Tablets 500mg, 60 Tablets per bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Plot No. 2, Phase-2, Pharma Zone SEZ, Pithampur Dist - Dhar, Madhya Pradesh - 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, NDC 68462-319-60.

Reason

Failed Dissolution Specifications: Out of specification for dissolution.

Identifiers

ndc68462-319-60
ndc68462-319-05
ndc68462-320-60
ndc68462-320-05
code_infoLot # 17230388, Exp. 01/31/2025

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0092-2024%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.